HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Pancreatic Cancer.
Eli Lilly, Boehringer Ingelheim get approval to expand Jardiance, Synjardy labels to kids with type 2 diabetes
Eli Lilly and Boehringer Ingelheim won FDA approval to expand empagliflozin’s label to include adolescents with type 2 diabetes. The SGLT2 inhibitor, better known as